CSF3 and acute myeloid leukemia: Zhang et al. compared HCAG therapy (CAG + Homoharringtonine) with FLAG (fudarabine, ara-C and G-CSF) as induction regimens in patients with refractory AML and found no statistically significant difference in CR and OOR [56].